Lobe Sciences Ltd provides update on clinical development of its proprietary psilocin compound L-130

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has received regulatory clearance to conduct a Phase 1 study evaluating the safety and pharmacokinetics of...

Related Keywords

Australia ,Maghsoud Dariani ,Philipj Young ,Lobe Sciences Ltd ,Lobe Sciences ,Clearway Global ,Orphan Drug Application ,Priority Review Voucher ,